Article

Topical cyclosporine applied after LASIK can restore corneal sensitivity sooner

Topical cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) following LASIK can significantly improve corneal sensitivity, possibly by accelerating corneal nerve regeneration in the LASIK flap, reported Gholam A. Peyman, MD, Department of Ophthalmology and Vision Science, University of Arizona, Tucson.

Topical cyclosporine 0.05% ophthalmic emulsion (Restasis, Allergan) following LASIK can significantly improve corneal sensitivity, possibly by accelerating corneal nerve regeneration in the LASIK flap, reported Gholam A. Peyman, MD, Department of Ophthalmology and Vision Science, University of Arizona, Tucson.

In a prospective, randomized, single-center study, 38 eyes of 19 patients were enrolled, Dr. Peyman said during an Innovator's Session. The study eye of each patient received one drop of topical cyclosporine b.i.d. with standard postoperative medications. The patient's control eye only received the standard postoperative medications, not the topical cyclosporine.

Corneal sensitivity was measured with the Cochet-Bonnet esthesiometer at four time periods (1 day, 1 week, 1 month, and 3 months postop). Nine different areas of the cornea were assessed: four untreated quadrants outside of the corneal flap and five areas within the flap. The areas outside of the flap had normal corneal sensitivity at all postoperative time periods. The areas within the flap had decreased corneal sensitivity after LASIK.

"At 3 months postop, there was greater corneal sensitivity recovery in treated eyes [with topical cyclosporine] than in control eyes," Dr. Peyman said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.